New drug combo aims to stop dangerous transplant complication in kids
NCT ID NCT06995521
Summary
This study is testing whether adding the drug vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults receiving bone marrow transplants for non-cancerous blood disorders. Researchers will enroll 55 patients aged 1-26 years to see if this combination improves survival without GVHD compared to older treatment approaches. The trial focuses on safety and effectiveness of this new prevention strategy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.